Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. WHO. 69th World Health Assembly 2016, document A69/32. 2016.
http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1
. Accessed 29 Mar 2018.
2. AbbVie GmbH & Co. KG (2018) Viekirax—Summary of Product Characteristics [accessed March 12, 2018]. Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf
.
3. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603.
4. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14.
5. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;47:359–65.